Inflammation, extracellular matrix remodelling, and vascular smooth muscle dysfunction are three hallmarks of AAA pathology. By examining the drug targets and data for each drug's ability to regulate the aforementioned three hallmark pathways in AAA progression, we discuss drugs for AAA treatment that have been studied in clinical trials. In the past, repurposed therapeutics was the drugs that were tested in interventional clinical trials to treat AAA.New treatments (like biologics, compounds with small molecules, etc.)Have stalled out in pre-clinical studies because they have been unable to reach the clinic. IN an effort to better inform the development of potential therapeutics in the future, we discuss the background of previous investigational drugs in this article. In general, the emphasized topics discussed here emphasize the significance of centralized anti-inflammatory drug targets and the precision of translation. Despite interventional treatment being the therapeutic approach used to treat AAA in a clinical setting, extremely few murine studies have examined the effectiveness of an intervention-based drug treatment in halting further growth of an established AAA.A central inflammatory biomarker may also be a potential drug target, according to the data. Specifically, one that is capable of effectively modulating not only inflammation but also the other two major contributors to AAA formation. To this end, it is suggested that the most important drug target for AAA treatment is an mPGES inhibitor that prevents PGE formation. The global healthcare system faces a threat from Alzheimer's disease's rapid progression, which is exacerbated by therapeutic failure. By 2050, it is anticipated that this disorder's prevalence will quadruple, putting a significant financial strain on the medical industry worldwide. As a result, a novel method of disease prevention, treatment, and diagnosis is urgently required and conventional methods must be altered. A tailored therapeutic approach is provided by precision medicine, which is based on genetic, environmental, and lifestyle factors associated with the individual and provides a personalized approach to disease management.Worldwide, initiatives aimed at facilitating the integration of personalized models and clinical medicine are being launched.The purpose of the review is to provide a concise overview of the disease interventions and a comprehensive understanding of the neuroinflammatory processes that cause AD.The role of precision medicine in AD, which encompasses genetic perspectives, the operation of personalized medicine, and the optimization of clinical trials with the, demonstrates an in-depth understanding of this novel approach in various aspects of the healthcare industry to provide global AD researchers with an opportunity to elucidate suitable therapeutic regimens for clinically and pathologically complex diseases like AD. This review article is the first to compile the published literature for molecular docking that was subsequently validated by in vitro and in vivo assays to predict and develop insights into the medicinal properties of SA in terms of anti-oxidation, anti-inflammation, and anti-diabetes in order to better understand the pharmacological characteristics of syringaldehyde, a key odorant compound of whisky and brandy. When there was inflammation caused by myocardial infarction or spinal cord ischemia, the molecular docking showed that SA had a significant amount of binding affinity for tumor necrosis factor-, interleukin-6, and antioxidant enzymes. In addition, in anti-diabetes research, SA docked well with dipeptidyl peptidase-IV, the glucagon-like peptide 1 receptor, the peroxisome proliferator-activated receptor, the acetylcholine M2 receptor, and acetylcholinesterase. These are linked to an increase in glucose utilization and insulin sensitivity, which results in an anti-hyperglycemic effect. They also increase intestinal contractility, which stops the -amylase reaction and simultaneously shortens the time it takes for the intestinal tract to absorb glucose, which results in a glucose-lowering effect. Combining in silico screening of multiple targets with preclinical testing could lead to the discovery of brand-new drug applications. A lot of attention has been paid to medicine nanotechnology as a novel and useful method for drug delivery systems in the treatment of cancer.Because of their exceptional advantages, such as biocompatibility, biodegradability, non-toxicity, and gelling properties, polysaccharides like cellulose, -cyclodextrin, sodium carboxymethyl cellulose, and chitosan, which are natural biomaterials, are suitable candidates for the design and formulation of these nanosystems.These hybrids are the foundation for a new intelligent drug delivery platform that can be utilized for dual-responsive dual-drug delivery.The possibility of combining nanotechnology with biological molecules to lessen the drawbacks of conventional cancer treatments has been carefully considered. As a consequence of this, the purpose of this review is to state and investigate the most recent advancements in the treatment of platforms based on hybrids of anticancer drugs nanoparticles Polysaccharides in the fields of biomedical therapeutics and cancer therapy. Due to their biocompatibility, large surface area, and excellent chemical and mechanical properties, these platforms also present challenges and offer potential solutions for the future.

With Regards,
Sara Giselle
Associate Managing Editor
 Journal of Critical Care Obsestrics & Gynocology